



REMINGTON

The Science and Practice of Pharmacy

20TH EDITION

Editor: Daniel Limmer
Managing Editor: Matthew J. Hauber
Marketing Manager: Anne Smith

Lippincott Williams & Wilkins

351 West Camden Street
Baltimore, Maryland 21201-2436 USA

227 East Washington Square
Philadelphia, PA 19106

All rights reserved. This book is protected by copyright. No part of this book may be reproduced in any form or by any means, including photocopying, or utilized by any information storage and retrieval system without written permission from the copyright owner.

The publisher is not responsible (as a matter of product liability, negligence or otherwise) for any injury resulting from any material contained herein. This publication contains information relating to general principles of medical care which should not be construed as specific instructions for individual patients. Manufacturers' product information and package inserts should be reviewed for current information, including contraindications, dosages and precautions.

Printed in the United States of America

Entered according to Act of Congress, in the year 1885 by Joseph P Remington, in the Office of the Librarian of Congress, at Washington DC

Copyright 1889, 1894, 1905, 1907, 1917, by Joseph P Remington

Copyright 1926, 1936, by the Joseph P Remington Estate

Copyright 1948, 1951, by the Philadelphia College of Pharmacy and Science

Copyright 1956, 1960, 1965, 1970, 1975, 1980, 1985, 1990, 1995, by the Philadelphia College of Pharmacy and Science

Copyright 2000, by the University of the Sciences in Philadelphia

All Rights Reserved
Library of Congress Catalog Card Information is available
ISBN 0-683-306472

The publishers have made every effort to trace the copyright holders for borrowed material. If they have inadvertently overlooked any, they will be pleased to make the necessary arrangements at the first opportunity.

The use of structural formulas from USAN and the USP Dictionary of Drug Names is by permission of The USP Convention. The Convention is not responsible for any inaccuracy contained herein.

Notice—This text is not intended to represent, nor shall it be interpreted to be, the equivalent of or a substitute for the official United States Pharmacopeia (USP) and/or the National Formulary (NF). In the event of any difference or discrepancy between the current official USP or NF standards of strength, quality, purity, packaging and labeling for drugs and representations of them herein, the context and effect of the official compendia shall prevail.

To purchase additional copies of this book call our customer service department at (800) 638-3030 or fax orders to (301) 824-7390. International customers should call (301) 714-2324.

00 01 02 03 04
1 2 3 4 5 6 7 8 9 10

0600-2000
0600-2000
0600-2000
0600-2000

LIBRARY OF CONGRESS
DEC 7 2000

Table of Contents

Part 1 Orientation			
1	Scope of Pharmacy	3	
2	Evolution of Pharmacy	7	
3	Ethics and Professionalism	19	
4	The Practice of Community Pharmacy	28	
5	Pharmacists in Industry	33	
6	Pharmacists in Government	38	
7	Pharmacists and Public Health	47	
8	Information Resources in Pharmacy and the Pharmaceutical Sciences	60	
9	Clinical Drug Literature	70	
10	Research	81	
Part 2 Pharmaceutics			
11	Pharmaceutical Calculations	91	
12	Statistics	124	
13	Molecular Structure, Properties, and States of Matter	159	
14	Complex Formation	183	
15	Thermodynamics	198	
16	Solutions and Phase Equilibria	208	
17	Ionic Solutions and Electrolytic Equilibria	227	
18	Tonicity, Osmoticity, Osmolality, and Osmolarity	246	
19	Chemical Kinetics	263	
20	Interfacial Phenomena	275	
21	Colloidal Dispersions	288	
22	Coarse Dispersions	316	
23	Rheology	335	
Part 3 Pharmaceutical Chemistry			
24	Inorganic Pharmaceutical Chemistry	359	
25	Organic Pharmaceutical Chemistry	385	
26	Natural Products	409	
27	Drug Nomenclature—United States Adopted Names	441	
28	Structure-Activity Relationship and Drug Design	458	
29	Fundamentals of Radionuclides	469	
Part 4 Pharmaceutical Testing, Analysis and Control			
30	Analysis of Medicinals	485	
31	Biological Testing	540	
32	Clinical Analysis	552	
33	Chromatography	587	
34	Instrumental Methods of Analysis	614	
35	Dissolution	654	
Part 5 Pharmaceutical Manufacturing			
36	Separation	669	
37	Powders	681	
38	Preformulation	700	
39	Solutions, Emulsions, Suspensions, and Extracts	721	
40	Sterilization	753	
41	Parenteral Preparations	780	
42	Intravenous Admixtures	807	
43	Ophthalmic Preparations	821	
44	Medicated Topicals	836	
45	Oral Solid Dosage Forms	858	
46	Coating of Pharmaceutical Dosage Forms	894	
47	Controlled-Release Drug-Delivery Systems	903	
48	The Introduction of New Drugs	930	
49	Biotechnology and Drugs	944	
50	Aerosols	963	
51	Quality Assurance and Control	980	
52	Stability of Pharmaceutical Products	986	
53	Bioavailability and Bioequivalency Testing	995	
54	Plastic Packaging Materials	1005	
55	Pharmaceutical Necessities	1015	
Part 6 Pharmacodynamics			
56	Diseases: Manifestations and Pathophysiology	1053	
57	Drug Absorption, Action, and Disposition	1098	
58	Basic Pharmacokinetics	1127	
59	Clinical Pharmacokinetics	1145	
60	Principles of Immunology	1156	
61	Adverse Drug Reactions	1165	
62	Pharmacogenetics	1169	
63	Pharmacological Aspects of Substance Abuse	1175	
Part 7 Pharmaceutical and Medicinal Agents			
64	Diagnostic Drugs and Reagents	1185	
65	Topical Drugs	1200	
66	Gastrointestinal and Liver Drugs	1219	
67	Blood, Fluids, Electrolytes, and Hematological Drugs	1243	
68	Cardiovascular Drugs	1274	
69	Respiratory Drugs	1297	
70	Sympathomimetic Drugs	1305	
71	Cholinomimetic Drugs	1314	
72	Adrenergic and Adrenergic Neuron Blocking Drugs	1322	
73	Antimuscarinic and Antispasmodic Drugs	1328	
74	Skeletal Muscle Relaxants	1333	
75	Diuretic Drugs	1344	
76	Uterine and Antimigraine Drugs	1354	
77	Hormones and Hormone Antagonists	1358	
78	General Anesthetics	1395	
79	Local Anesthetics	1400	
80	Sedative and Hypnotic Drugs	1407	
81	Antiepileptic Drugs	1421	
82	Psychopharmacologic Agents	1429	
83	Analgesic, Antipyretic, and Anti-Inflammatory Drugs	1444	
84	Histamine and Antihistaminic Drugs	1464	
85	Central Nervous System Stimulants	1471	
86	Antineoplastic and Immunoactive Drugs	1477	
87	Anti-Infectives	1507	
88	Parasiticides	1562	
89	Immunizing Agents and Allergenic Extracts	1567	
Part 8 Pharmacy Practice			
Part 8A Pharmacy Administration			
90	Laws Governing Pharmacy	1595	
91	Pharmacoeconomics	1625	
92	Marketing Pharmaceutical Care Services	1634	
93	Documenting and Billing for Pharmaceutical Care Services	1640	
94	Community Pharmacy Economics and Management	1650	
95	Product Recalls and Withdrawals	1666	
Part 8B Fundamentals of Pharmacy Practice			
96	Drug Education	1677	

97 The Prescription	1687	113 The Patient: Behavioral Determinants	1948
98 Extemporaneous Prescription Compounding	1706	114 Patient Communication	1957
99 Poison Control	1716	115 Patient Compliance	1966
100 Nutrition in Pharmacy Practice	1725	116 Pharmacoepidemiology	1980
101 Self-Care/Diagnostic Products	1738	117 Integrated Health-Care Delivery Systems	1990
102 Drug Interactions	1746	118 Home Health Patient Care	2012
103 Complementary and Alternative Medical Health Care	1762	119 Aseptic Technology for Home-Care Pharmaceuticals	2020
104 Nuclear Pharmacy Practice	1781		
105 Enzymes	1792	Appendixes	
106 Vitamins and Other Nutrients	1796	Dose Equivalents	2033
107 Pesticides	1825	Periodic Chart	2034
108 Surgical Supplies	1846	Logarithms	2036
109 Health Accessories	1857		
		Glossary and Index	
Part 8C Patient Care		Glossary	2037
110 Ambulatory Patient Care	1893	Index	2039
111 Institutional Patient Care	1911		
112 Long-Term Care Facilities	1932		

Coating of Pharmaceutical Dosage Forms

Stuart C Porter, PhD

President
PPT
Hatfield, PA 19440

Any introduction to tablet coating must be prefaced by an important question—*Why coat tablets?*—since in many instances, the coating is being applied to a dosage form that already is functionally complete. In attempting to answer this question, if one examines the market, it will become apparent that a significant proportion of pharmaceutical solid dosage forms are coated. The reasons for this range from the esthetic to a desire to control the bioavailability of the drug, and include

1. Protecting the drug from its surrounding environment (particularly air, moisture, and light) with a view to improving stability.
2. Masking of unpleasant taste and odor.
3. Increasing the ease by which the product can be ingested by the patient.
4. Improving product identity, from the manufacturing plant, through intermediaries, and to the patient.
5. Facilitating handling, particularly in high-speed packaging/filling lines, and automated counters in pharmacies, where the coating minimizes cross-contamination due to dust elimination.
6. Improving product appearance, particularly where there are noticeable visible differences in tablet core ingredients from batch to batch.
7. Reducing the risk of interaction between incompatible components. This would be achieved by using coated forms of one or more of the offending ingredients (particularly active compounds).
8. Improving product mechanical integrity, since coated products generally are more resistant to mishandling (abrasion, attrition, etc).
9. Modifying drug release, as in enteric-coated, repeat-action and sustained-release products.

EVOLUTION OF THE COATING PROCESS—Tablet coating is perhaps one of the oldest pharmaceutical processes still in existence. Historically, the literature cites Rhazes (850–932 AD) as being one of the earliest *tablet coaters*, having used the mucilage of psyllium seeds to coat pills that had an offending taste. Subsequently, Avicenna¹ was reported to have used gold and silver for pill coating. Since then, there have been many references to the different materials used in *tablet coating*. White² mentioned the use of finely divided talc in what was at one time popularly known as *pearl coating*, while Kremers and Urdang³ described the introduction of the gelatin coating of pills by Garot in 1838.

An interesting reference⁴ reports the use of waxes to coat poison tablets. These waxes, being insoluble in all parts of the gastrointestinal tract, were intended to prevent accidental poisoning (the contents could be utilized by breaking the tablet prior to use).

While earlier coated products were produced by individuals working in pharmacies, particularly when extemporaneous compounding was the order of the day, that responsibility now has been assumed by the pharmaceutical industry. The earliest attempts to apply coatings to pills yielded variable results and usually required the handling of single pills. Such pills would have been mounted on a needle or held with a pair of forceps and literally dipped into the coating fluid, a procedure that would have to be repeated more than once to ensure that the

pill was coated completely. Subsequently, the pills were held at the end of a suction tube, dipped, and then the process repeated for the other side of the pill. Not surprisingly, these techniques often failed to produce a uniformly coated product.⁵

Initially, the first sugar-coated pills seen in the US were imported from France about 1842⁵; while Warner, a Philadelphia pharmacist, became among the first indigenous manufacturers in 1856.⁶

Pharmaceutical pan-coating processes are based on those used in the candy industry, where techniques were highly evolved, even in the Middle Ages. Today most coating pans are fabricated from stainless steel, while early pans were made from copper, because drying was effected by means of an externally applied heat source. Current thinking, even with conventional pans, is to dry the coated tablets with a supply of heated air and remove the moisture and dust-laden air from the vicinity of the pan by means of an air-extraction system.

Pan-coating processes underwent little further change until the late 1940s and early 1950s, with the conventional pan being the mainstay of all coating operations up to that time. However, in the last 30 or 40 years there have been some significant advances made in coating-process technology, mainly as a result of a steady evolution in pan design and its associated ancillary equipment.

Interestingly, in the early years of this development, an entirely new form of technology evolved, that of film coating. Recognizing the deficiencies of the sugar-coating process, advocates of film coating were achieving success by using coating systems involving highly volatile organic solvents.

These solvents circumvented the problems associated with the inefficiency in the drying capabilities of conventional equipment and enabled production quotas to be met with significant reductions in processing times and materials used. The disadvantage of this approach, however, always has been associated with the fact that the solvents used were often flammable and toxic.

The advances that occurred with equipment design, having begun by the development of the Wurster⁷ process and continued by the evolution of side-vented pans, have resulted in the gradual emergence of coating processes in which drying efficiency can be maximized. Thus, film coating began as a process using inefficient drying equipment, relying on highly volatile coating formulations for success, and evolved into one in which the processing equipment is a major factor in ensuring that rapid drying occurs. Improved drying capabilities have permitted common use of aqueous film-coating formulations.

Advances in equipment design also have benefited the sugar-coating process, where, because of current Good Manufacturing Practices (cGMP) and to maintain product uniformity and performance, the trend has been toward using fully automated processes. Nonetheless, film coating tends to dominate as the process of choice for tablet coating.

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.